2024
Win Ratio Analyses Using a Modified Hierarchical Composite Outcome: Insights from PARAGLIDE-HF
Shoji S, Cyr D, Hernandez A, Velazquez E, Ward J, Williamson K, Sarwat S, Starling R, Desai A, Zieroth S, Solomon S, Mentz R. Win Ratio Analyses Using a Modified Hierarchical Composite Outcome: Insights from PARAGLIDE-HF. American Heart Journal 2024 PMID: 39505123, DOI: 10.1016/j.ahj.2024.10.020.Peer-Reviewed Original ResearchNT-proBNPComposite outcomeRenal outcomesEjection fractionHeart failureN-terminal pro-B-type natriuretic peptidePro-B-type natriuretic peptideNT-proBNP thresholdsNT-proBNP changesClinically significant eventsNatriuretic peptideAssessment of treatment effectsHF hospitalizationCardiovascular deathTreatment effectsTreatment benefitComprehensive assessment of treatment effectsPrimary analysisValsartanHF visitsSecondary analysisPatientsHierarchical outcomesOutcomesEfficacy And Safety Of Sacubitril/valsartan In Patients Hospitalized With Heart Failure: A Prespecified, Pooled Individual Patient-level Analysis Of PIONEER-HF And PARAGLIDE-HF
Morrow D, Velazquez E, Desai A, DeVore A, Lepage S, Park J, Sharma K, Solomon S, Starling R, Ward J, Williamson K, Zieroth S, Hernandez A, Mentz R, Braunwald E. Efficacy And Safety Of Sacubitril/valsartan In Patients Hospitalized With Heart Failure: A Prespecified, Pooled Individual Patient-level Analysis Of PIONEER-HF And PARAGLIDE-HF. Journal Of Cardiac Failure 2024, 30: 312-313. DOI: 10.1016/j.cardfail.2023.10.467.Peer-Reviewed Original ResearchSacubitril/valsartanPIONEER-HFHeart failurePooled analysisNT-proBNPControl therapyDe novo heart failurePlasma NT-proBNP levelsIndependent clinical events committeeIndividual patient-level analysisNovo heart failureNT-proBNP levelsClinical events committeePatient-level analysisCardiovascular deathHemodynamic stabilizationPrimary endpointSymptomatic hypotensionRenal functionMedian ageClinical outcomesRandomized trialsClinical effectsEvents committeeHF events
2023
Angiotensin-Neprilysin Inhibition in Patients With Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure
Mentz R, Ward J, Hernandez A, Lepage S, Morrow D, Sarwat S, Sharma K, Starling R, Velazquez E, Williamson K, Desai A, Zieroth S, Solomon S, Braunwald E, Investigators P. Angiotensin-Neprilysin Inhibition in Patients With Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure. Journal Of The American College Of Cardiology 2023, 82: 1-12. PMID: 37212758, DOI: 10.1016/j.jacc.2023.04.019.Peer-Reviewed Original ResearchConceptsSacubitril/valsartanEjection fractionWHF eventNT-proBNPSymptomatic hypotensionHeart failureAmino-terminal pro-B-type natriuretic peptideTerminal pro-B-type natriuretic peptidePro-B-type natriuretic peptidePlasma NT-proBNP levelsAngiotensin-Neprilysin InhibitionNT-proBNP changesNT-proBNP levelsUrgent HF visitsChronic heart failureHeart failure eventsLarge treatment effectsHF hospitalizationHF visitsCardiovascular deathPrimary endpointRenal functionClinical benefitNatriuretic peptideWeek 4Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF
Vaduganathan M, Mentz R, Claggett B, Miao Z, Kulac I, Ward J, Hernandez A, Morrow D, Starling R, Velazquez E, Williamson K, Desai A, Zieroth S, Lefkowitz M, McMurray J, Braunwald E, Solomon S. Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF. European Heart Journal 2023, 44: 2982-2993. PMID: 37210743, PMCID: PMC10424880, DOI: 10.1093/eurheartj/ehad344.Peer-Reviewed Original ResearchConceptsSacubitril/valsartanRenal composite endpointPARAGON-HFHeart failureEjection fractionPooled analysisHF eventsRenal eventsCardiovascular deathComposite endpointLeft ventricular ejection fractionVentricular ejection fractionActive-controlled trialParticipant-level dataPrimary endpointSecondary endpointsClinical outcomesNatriuretic peptideLike patientsTreatment benefitCare settingsPatientsPrimary analysisLVEFValsartan
2022
Pragmatic trial of messaging to providers about treatment of acute heart failure: The PROMPT-AHF trial
Ghazi L, O'Connor K, Yamamoto Y, Fuery M, Sen S, Samsky M, Riello R, Huang J, Olufade T, McDermott J, Inzucchi S, Velazquez E, Wilson F, Desai N, Ahmad T. Pragmatic trial of messaging to providers about treatment of acute heart failure: The PROMPT-AHF trial. American Heart Journal 2022, 257: 111-119. PMID: 36493842, DOI: 10.1016/j.ahj.2022.12.002.Peer-Reviewed Original ResearchConceptsGuideline-directed medical therapyAcute heart failureHeart failurePragmatic trialElectronic health recordsSubstantial health care costsBest practice advisoryReduced ejection fractionUsual care armHealth recordsTime of dischargeEvidence-based careHealth care costsClinical decision support systemAHF patientsCare armEligible patientsHF hospitalizationInpatient initiationCardiovascular deathMedication classesEjection fractionMedical therapyPrimary outcomePractice advisory
2020
Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure
DeVore AD, Braunwald E, Morrow DA, Duffy CI, Ambrosy AP, Chakraborty H, McCague K, Rocha R, Velazquez EJ. Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure. JAMA Cardiology 2020, 5: 202-207. PMID: 31825471, PMCID: PMC6990764, DOI: 10.1001/jamacardio.2019.4665.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAgedAminobutyratesAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsBiphenyl CompoundsDrug CombinationsEnalaprilFemaleHeart FailureHospitalizationHumansMaleMiddle AgedNatriuretic Peptide, BrainNeprilysinPatient DischargePeptide FragmentsTetrazolesValsartanConceptsAcute decompensated heart failureSacubitril/valsartanNT-proBNP levelsDecompensated heart failureOpen-label studyReduced ejection fractionHospital initiationHeart failurePIONEER-HFEjection fractionWeek 8N-terminal pro-B-type natriuretic peptide levelsPro-B-type natriuretic peptide levelsOpen-label extension phaseAngiotensin-Neprilysin InhibitionHeart failure rehospitalizationPIONEER-HF trialWeek 8 visitNatriuretic peptide levelsActive-controlled trialCardiovascular deathComposite outcomeHemodynamic stabilityRecent hospitalizationClinical outcomes
2019
Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial
Morrow DA, Velazquez EJ, DeVore AD, Prescott MF, Duffy CI, Gurmu Y, McCague K, Rocha R, Braunwald E. Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial. European Heart Journal 2019, 40: 3345-3352. PMID: 31093657, PMCID: PMC6801941, DOI: 10.1093/eurheartj/ehz240.Peer-Reviewed Original ResearchConceptsSacubitril/valsartanAcute decompensated HFAcute decompensated heart failureSoluble ST2Decompensated heart failureHeart failureUrinary cGMPMyocardial stressHigh-sensitivity cardiac troponinCyclic guanosine 3'5PIONEER-HF trialDouble-blind trialReduced ejection fractionMultivariable-adjusted analysesGreater reductionNatriuretic peptide receptorPIONEER-HFCardiovascular deathCardiac afterloadHaemodynamic stabilizationEjection fractionHospitalized patientsMyocardial injuryCardiovascular biomarkersTreatment groups
2016
Ten-Year Outcomes After Coronary Artery Bypass Grafting According to Age in Patients With Heart Failure and Left Ventricular Systolic Dysfunction
Petrie MC, Jhund PS, She L, Adlbrecht C, Doenst T, Panza JA, Hill JA, Lee KL, Rouleau JL, Prior DL, Ali IS, Maddury J, Golba KS, White HD, Carson P, Chrzanowski L, Romanov A, Miller AB, Velazquez EJ. Ten-Year Outcomes After Coronary Artery Bypass Grafting According to Age in Patients With Heart Failure and Left Ventricular Systolic Dysfunction. Circulation 2016, 134: 1314-1324. PMID: 27573034, PMCID: PMC5089908, DOI: 10.1161/circulationaha.116.024800.Peer-Reviewed Original ResearchConceptsCoronary artery bypassCause mortalityMedical therapyCardiovascular mortalityYounger patientsEjection fractionHeart failureCABG groupArtery bypassOlder patientsCardiovascular hospitalizationBenefit of CABGEfficacy of CABGCardiopulmonary bypass timeReduced ejection fractionVentricular systolic dysfunctionBaseline ejection fractionCoronary artery diseaseEffect of CABGTen-year outcomesConsistent beneficial effectsMore comorbiditiesSTICH trialBypass timeCardiovascular deathPredicting Outcomes Over Time in Patients With Heart Failure, Left Ventricular Systolic Dysfunction, or Both Following Acute Myocardial Infarction
Lopes RD, Pieper KS, Stevens SR, Solomon SD, McMurray JJ, Pfeffer MA, Leimberger JD, Velazquez EJ. Predicting Outcomes Over Time in Patients With Heart Failure, Left Ventricular Systolic Dysfunction, or Both Following Acute Myocardial Infarction. Journal Of The American Heart Association 2016, 5: e003045. PMID: 27353607, PMCID: PMC4937254, DOI: 10.1161/jaha.115.003045.Peer-Reviewed Original ResearchConceptsVentricular systolic dysfunctionHeart failureMyocardial infarctionIntegrated discrimination improvementSystolic dysfunctionCardiovascular deathMultivariable Cox proportional hazardsAcute Myocardial Infarction trialNet reclassification improvement indexNonfatal heart failureMyocardial Infarction trialNonfatal myocardial infarctionPredictors of mortalityPatient informationBaseline heart rateAcute myocardial infarctionCox proportional hazardsCreatinine clearanceHospital arrivalHospital dischargeIndex hospitalizationPatient characteristicsOverall mortalityIndex eventClinical events
2015
Sex differences in clinical characteristics and outcomes after myocardial infarction: insights from the Valsartan in Acute Myocardial Infarction Trial (VALIANT)
Lam CS, McEntegart M, Claggett B, Liu J, Skali H, Lewis E, Køber L, Rouleau J, Velazquez E, Califf R, McMurray JJ, Pfeffer M, Solomon S. Sex differences in clinical characteristics and outcomes after myocardial infarction: insights from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). European Journal Of Heart Failure 2015, 17: 301-312. PMID: 25655011, DOI: 10.1002/ejhf.238.Peer-Reviewed Original ResearchConceptsAcute Myocardial Infarction trialMyocardial Infarction trialVentricular systolic dysfunctionHeart failureMyocardial infarctionSystolic dysfunctionClinical characteristicsVentricular volumeKillip class III/IVLeft ventricular systolic dysfunctionRisk of HFClass III/IVHigher long-term riskSmaller left ventricular volumesSimilar ejection fractionLong-term mortalityPost-infarction anginaRisk of hospitalizationSubset of patientsNon-fatal outcomesLong-term riskLeft ventricular volumeAssociation of sexMore comorbiditiesCardiovascular death
2013
The STICH Trial (Surgical Treatment for Ischemic Heart Failure) Mode-of-Death Results
Carson P, Wertheimer J, Miller A, O'Connor CM, Pina IL, Selzman C, Sueta C, She L, Greene D, Lee KL, Jones RH, Velazquez EJ, Investigators S. The STICH Trial (Surgical Treatment for Ischemic Heart Failure) Mode-of-Death Results. JACC Heart Failure 2013, 1: 400-408. PMID: 24621972, PMCID: PMC3829618, DOI: 10.1016/j.jchf.2013.04.012.Peer-Reviewed Original ResearchConceptsMode of deathIschemic cardiomyopathy patientsMedical therapySTICH trialMyocardial infarction deathsCABG therapyCardiomyopathy patientsSudden deathProspective clinical trial dataAddition of CABGStrategy of CABGCoronary artery bypassReduced ejection fractionClinical events committeeClinical trial dataPre-specified definitionsCABG patientsArtery bypassCardiovascular deathNoncardiovascular deathEjection fractionHeart failureEvents committeeProtective effectCABGPrediction of All-Cause Mortality and Heart Failure Admissions From Global Left Ventricular Longitudinal Strain in Patients With Acute Myocardial Infarction and Preserved Left Ventricular Ejection Fraction
Ersbøll M, Valeur N, Mogensen UM, Andersen MJ, Møller JE, Velazquez EJ, Hassager C, Søgaard P, Køber L. Prediction of All-Cause Mortality and Heart Failure Admissions From Global Left Ventricular Longitudinal Strain in Patients With Acute Myocardial Infarction and Preserved Left Ventricular Ejection Fraction. Journal Of The American College Of Cardiology 2013, 61: 2365-2373. PMID: 23563128, DOI: 10.1016/j.jacc.2013.02.061.Peer-Reviewed Original ResearchMeSH KeywordsAgedCause of DeathCohort StudiesConfidence IntervalsEchocardiography, DopplerFemaleHeart FailureHumansMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionPredictive Value of TestsPrognosisProportional Hazards ModelsProspective StudiesRisk AssessmentSeverity of Illness IndexStroke VolumeSurvival RateVentricular Dysfunction, LeftConceptsGlobal longitudinal strainHeart failure hospitalizationVentricular ejection fractionAcute myocardial infarctionMyocardial infarctionFailure hospitalizationSecondary endpointsEjection fractionHigh-risk myocardial infarctionVentricular global longitudinal strainLeft ventricular ejection fractionLongitudinal strainHeart failure admissionsPrimary composite endpointCox regression analysisHigh-risk subjectsVentricular longitudinal strainImportant prognostic informationSignificant prognostic valueAssessment of GLSParticular clinical relevanceCardiovascular deathCause mortalityPrimary endpointCardiac deathSystolic Blood Pressure and Cardiovascular Outcomes During Treatment of Hypertension
Weber MA, Bakris GL, Hester A, Weir MR, Hua TA, Zappe D, Dahlof B, Velazquez EJ, Pitt B, Jamerson K. Systolic Blood Pressure and Cardiovascular Outcomes During Treatment of Hypertension. The American Journal Of Medicine 2013, 126: 501-508. PMID: 23541376, DOI: 10.1016/j.amjmed.2013.01.007.Peer-Reviewed Original ResearchConceptsSystolic blood pressureHigh-risk hypertensive patientsPrimary end pointBlood pressure levelsSystolic bloodBlood pressureCardiovascular deathCardiovascular eventsCardiovascular outcomesCoronary eventsEnd pointHypertensive patientsMyocardial infarctionSystolic blood pressure levelsAvoiding Cardiovascular EventsSystolic Hypertension (ACCOMPLISH) trialTotal myocardial infarctionBlood pressure groupMajor cardiovascular eventsMean patient ageNonfatal myocardial infarctionCardiovascular event ratesRenal end pointsLower blood pressureTreatment of hypertension
2012
Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial
Weber MA, Jamerson K, Bakris GL, Weir MR, Zappe D, Zhang Y, Dahlof B, Velazquez EJ, Pitt B. Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. The Lancet 2012, 381: 537-545. PMID: 23219284, DOI: 10.1016/s0140-6736(12)61343-9.Peer-Reviewed Original ResearchConceptsCardiovascular event ratesBody mass indexNormal weightPrimary endpointObese patientsEvent ratesCardiovascular outcomesCardiovascular protectionHypertension treatmentObese individualsHigher cardiovascular event ratesHigh-risk hypertensive patientsNon-fatal myocardial infarctionAmlodipine-based therapyAvoiding Cardiovascular EventsPatient’s cardiovascular outcomeSuperior cardiovascular protectionSystolic Hypertension (ACCOMPLISH) trialPrimary event rateSingle-pill combinationPrevious clinical trialsNormal weight categoryCardiovascular deathCardiovascular eventsHypertension trials
2010
Cardiovascular Events During Differing Hypertension Therapies in Patients With Diabetes
Weber MA, Bakris GL, Jamerson K, Weir M, Kjeldsen SE, Devereux RB, Velazquez EJ, Dahlöf B, Kelly RY, Hua TA, Hester A, Pitt B, Investigators A. Cardiovascular Events During Differing Hypertension Therapies in Patients With Diabetes. Journal Of The American College Of Cardiology 2010, 56: 77-85. PMID: 20620720, DOI: 10.1016/j.jacc.2010.02.046.Peer-Reviewed Original ResearchConceptsRenin-angiotensin system blockersDiabetic patientsCardiovascular eventsSystem blockersHigh riskPrimary end pointAcute clinical eventsUnexpected adverse eventsPrimary eventACCOMPLISH trialCoronary benefitNondiabetic patientsCardiovascular deathCoronary revascularizationDiabetes groupAdverse eventsBlood pressureHypertension therapyClinical eventsCombination therapyMyocardial infarctionPatientsDiabetesHypertensionEnd point
2009
Patients with prior coronary artery bypass grafting have a poor outcome after myocardial infarction: an analysis of the VALsartan in acute myocardial iNfarcTion trial (VALIANT)
Berry C, Pieper KS, White HD, Solomon SD, Van de Werf F, Velazquez EJ, Maggioni AP, Califf RM, Pfeffer MA, McMurray JJ. Patients with prior coronary artery bypass grafting have a poor outcome after myocardial infarction: an analysis of the VALsartan in acute myocardial iNfarcTion trial (VALIANT). European Heart Journal 2009, 30: 1450-1456. PMID: 19346225, DOI: 10.1093/eurheartj/ehp102.Peer-Reviewed Original ResearchConceptsPrior CABG patientsCoronary artery bypassMyocardial infarctionCABG patientsPrior CABGHeart failureArtery bypassNon-Q-wave myocardial infarctionPrior coronary artery bypassAcute Myocardial Infarction trialPrimary percutaneous coronary interventionKaplan-Meier ratesSecondary preventive therapyWorse clinical profileMyocardial Infarction trialVentricular systolic dysfunctionHigh-risk patientsPercutaneous coronary interventionAcute myocardial infarctionNumber of patientsNon-fatal outcomesHospital presentationLess aspirinMore comorbiditiesCardiovascular death
2008
Predictors of the first heart failure hospitalization in patients who are stable survivors of myocardial infarction complicated by pulmonary congestion and/or left ventricular dysfunction: a VALIANT study
Lewis EF, Velazquez EJ, Solomon SD, Hellkamp AS, McMurray JJ, Mathias J, Rouleau JL, Maggioni AP, Swedberg K, Kober L, White H, Dalby AJ, Francis GS, Zannad F, Califf RM, Pfeffer MA. Predictors of the first heart failure hospitalization in patients who are stable survivors of myocardial infarction complicated by pulmonary congestion and/or left ventricular dysfunction: a VALIANT study. European Heart Journal 2008, 29: 748-756. PMID: 18308687, DOI: 10.1093/eurheartj/ehn062.Peer-Reviewed Original ResearchConceptsHeart failure hospitalizationMyocardial infarctionFailure hospitalizationHigh-risk acute myocardial infarctionFirst heart failure hospitalizationHigh-risk myocardial infarctionStable post-MI patientsIndex myocardial infarctionRecurrent myocardial infarctionPrior myocardial infarctionLong-term survivorsPost-MI patientsRisk of deathAcute myocardial infarctionOnset of HFAntecedent diabetesTime-dependent fashionVALIANT studyCardiovascular deathInitial hospitalizationVentricular dysfunctionMost patientsRenal functionIndependent predictorsPrognostic factors
2007
Effect of Antecedent Hypertension and Follow-Up Blood Pressure on Outcomes After High-Risk Myocardial Infarction
Thune JJ, Signorovitch J, Kober L, Velazquez EJ, McMurray JJ, Califf RM, Maggioni AP, Rouleau JL, Howlett J, Zelenkofske S, Pfeffer MA, Solomon SD. Effect of Antecedent Hypertension and Follow-Up Blood Pressure on Outcomes After High-Risk Myocardial Infarction. Hypertension 2007, 51: 48-54. PMID: 18025296, DOI: 10.1161/hypertensionaha.107.093682.Peer-Reviewed Original ResearchConceptsHigh-risk myocardial infarctionLower blood pressureBlood pressureCardiovascular eventsMyocardial infarctionAntecedent hypertensionHeart failureElevated systolic blood pressureAggressive antihypertensive treatmentComposite of deathMyocardial Infarction trialSubsequent cardiovascular eventsVentricular systolic dysfunctionElevated blood pressureModifiable risk factorsSystolic blood pressureAcute myocardial infarctionPostmyocardial infarction periodAntihypertensive treatmentCardiovascular deathSystolic dysfunctionAdverse eventsCardiac arrestRisk factorsHigh risk
2006
Association of QRS duration and outcomes after myocardial infarction: the VALIANT trial
Yerra L, Anavekar N, Skali H, Zelenkofske S, Velazquez E, McMurray J, Pfeffer M, Solomon SD. Association of QRS duration and outcomes after myocardial infarction: the VALIANT trial. Heart Rhythm 2006, 3: 313-316. PMID: 16500304, DOI: 10.1016/j.hrthm.2005.11.024.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsCohort StudiesElectrocardiographyFemaleFollow-Up StudiesHeart VentriclesHumansMaleMiddle AgedMyocardial InfarctionPrognosisStroke VolumeSurvival RateTetrazolesTreatment OutcomeValineValsartanVentricular Dysfunction, LeftConceptsQRS durationSudden deathCV deathAdverse outcomesMyocardial infarctionPost-myocardial infarction settingUnivariate relative riskLeft ventricular dysfunctionHeart failure patientsSymptoms of HFAcute myocardial infarctionDevelopment of HFEnd-systolic volumeLarger ventricular volumesQRS duration prolongationRecurrent MICardiovascular deathInitial electrocardiogramVentricular dysfunctionAcute MIFailure patientsSystolic functionEjection fractionIndependent predictorsClinical outcomes